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Abstract 
The expression of Cyp2e-I mRNA and protein was investigated in the C57BL/6NCrj mouse hepatocytes in primary culture, as well 
as liver and kidney. The mRNA and protein expression in the liver was in the same range in both sexes and was not affected by 
orchiectomy or ovariectomy. The mRNA expression was enhanced in the kidney of ovariectomized mice, in which the protein contents 
were not influenced. Orchiecl:omy decreased the expression of both mRNA and protein. When the hepatocytes were transferred to primary 
culture, the amounts of the mRNA were not changed within 24 h and about half remained by day 3. However, the expression was low 
thereafter. The expression of the protein gradually decreased after the start of culture. Dexamethasone showed a potential as an inducer at 
more than 10 -8 M. Sex homaones increased the expression of this P-450 species a little in culture, but growth hormone did not. These 
observations indicated that glucocorticoid hormone plays a role in modifying expression of Cyp2e-I and that the mouse hepatocyte 
culture is useful for examining its regulation mechanism. 
Keywords: Cyp2e-l; Hepatocyte culture; Glucocorticoid hormone; Sex hormone 
1. Introduction 
Cytochrome P-450s participate in the metabolism of 
endogenous and exogenous substances, including chemical 
carcinogens [1]. CYP2EI proteins are responsible for the 
metabolism of several hepatotoxins [2,3], such as ac- 
etaminophen, carbon tetrachloride and benzene, and for 
activation of carcinogenic: nitroso compounds [ 1,4]. As was 
observed in other forms of P-450, it is induced by numer- 
ous structurally diverse compounds [5-12], many of which 
effectively bind to the enzyme protein, resulting in slowing 
turnover. Ethanol-medial:ed increases in CYP2E1 mRNA 
are reported in rats and human cases [13,14]. However, the 
mRNA expression is not always altered in accordance with 
that of the protein [1,15]. In some cases it is decreased 
[7,11,16,17]. Furthermore, expression is enhanced in fast- 
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ing or diabetic animals via mRNA transcription [18] or 
stabilization [19], which suggests endogenous regulatory 
factors for the expression. Although testosterone is a regu- 
lator of the expression in mouse kidney, which is depen- 
dent upon gender, its administration did not change the 
expression in other organs including the liver [4,20-24]. 
The androgen markedly affects the metabolism of nitroso 
compounds and carcinogenesis [20-23,25-27]. Further- 
more, the expression of CYP2E1 is suppressed by growth 
hormone in rats, but not in mice [28]. There is only one 
established cell line (Fao), derived from the Reuber H35 
rat bepatoma [29], which stably expresses this P-450 
species at low level and treatment with ethanol increased 
amounts of CYP2E1 apoprotein without affecting those of 
the mRNA [30], or with concomitant elevation of it [31]. 
Expression is the highest in the liver, but it decreases 
very rapidly, especially that of mRNA, after transferring 
hepatocytes to primary culture [7,32,33]. For example, in 
rat hepatocytes, the level of the mRNA is less than 10% 
within 24 h and is undetectable at day 3, whereas the 
enzyme protein decreases to about 70% of the original 
level within this period in the presence of ligand [7]. Thus 
a culture system, that maintains mRNA levels comparable 
to those in vivo for at least few days or in which activation 
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of the gene is possible, has not been reported. If available, 
regulating or modifying factors at the transcriptional level 
could be validated. 
This paper describes the maintenance of Cyp2e- 1 mRNA 
expression in mouse hepatocytes in primary culture and 
examines the effects of hormones upon the expression. The 
results indicated that glucocorticoid hormone activates 
Cyp2e-I expression, and that sex hormones change the 
expression a little, but growth hormone is not a functional 
modifier. 
2. Materials and methods 
2.1. Chemicals 
Materials for culturing hepatocytes were purchased from 
ICN Biomedicals, Costa Mesa, CA, Collaborative Re- 
search, Bedford, MA, and Kyokuto Seiyaku, Tokyo. Per- 
coll and collagenase were products of Pharmacia, Uppsala, 
and Sigma Chemical Co., St. Louis, MO, respectively. 
2.2. Preparation of primary cultures of hepatocytes 
The livers of C57BL/6NCrj mice (Charles River, Japan) 
at 8 week old, were perfused with collagenase, then viable 
hepatocytes were isolated by means of Percoll isodensity 
centrifugation as described [34,35]. Standard culture condi- 
tions were as follows. The cells were dispersed in Way- 
mouth MB 752/1 medium containing bovine serum albu- 
min (2 g/l),  insulin (0.5 mg/l),  transferrin (0.5 mg/1), 
and selenium (0.5 isg/1), and seeded at a density of 5 • 106 
cells/10 ml per 100 mm in collagen type I- coated or 
non-coated ish. The Waymouth medium did not contain 
phenol red, a pH indicator, to exclude estrogen-like action. 
The hepatocytes attached to the coated dish surface within 
a few hours and formed monolayers. In contrast, hepato- 
cytes seeded on the non-coated ishes did not spread, 
although they anchored to the dish surface and subse- 
quently aggregated. The aggregates gradually grew and 
detached to form floating spherical aggregates ( pheroids) 
after day 3. However, at day 5 of cultivation, about half of 
the aggregated mouse hepatocytes remained anchored to 
the dish. The culture dishes were maintained at 37°C in a 
CO2-humidified incubator. The medium was renewed ev- 
eryday. However, since a medium change by itself pro- 
vokes the expression of some P-450 species [36,37], expo- 
sure to either hormones or chemicals was started 24 h after 
the last medium change. 
2.3. Polymerase chain reaction of cDNAs 
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Fig. I. Product formation during PCR cycling. 1 I.zg of total RNA was 
reverse-transcribed, then submitted to PCR with following amplifing 
conditions: at 94°C for 60 s, 64°C for 90 s and then 72°C for 120 s. 
Portions of the reaction mixture at 15, 20, 25, 30 and 35 cycles were 
analyzed the formation of the products on polyacrylamide g l elec- 
trophoresis. Amounts were measured with a densitometer and arbitrarily 
determined by comparing those (= 100) found after 30 cycles. Close 
circle, products with Cyp2e-I mRNA primers; open squire, products with 
GAPDH primers. 
Lab.). The forward and reverse primers were 5'-GTTGC- 
CTTGCTTGTCTGGATCG-3 '  and 5' -CTTGTGGT- 
TCAGTAGCACCTCC-3', respectively. The PCR was per- 
formed 28 cycles, with 94°C for 60 s, 64°C for 90 s and 
then 72°C for 120 s. The product length was 261 bases, 
scanning the region from 22 to 282 of the open reading 
frame, with spliced 1st intron of about 800 bases. To 
verify the amplification of the target mRNA species, the 
PCR products were digested with various restriction en- 
zymes, such as Bgl II or Pvu II, then resolved by 10% 
polyacrylamide gel electrophoresis (PAGE). The digests 
separated into two bands as expected(data not shown). To 
normalize the applied RNA quantity, portions of the cDNA 
samples were simultaneously amplified by PCR using 
primers for GAPDH cDNA [39]. The nucleotide sequence 
of the forward primer was 5'-TCCACTCACGGCAAAT- 
TCAACG-3' and that of the reverse 5'-TAGACTCCAC- 
GACATACTCAGC-3'. The PCR was performed 24 cy- 
cles, with 94°C for 60 s, 64°C for 90 s and then 72°C for 
120 s. The PCR product length was 145 bases. Numbers of 
the PCR cycles were determined, at which instances the 
reactions proceeded exponentially (Fig. 1). 
cDNA was prepared from total RNA as reported [38]. 
Specific oligonucleotide primers were selected according 
to the genomic structure of Cyp2e-1 reported by Freeman 
et al. [16] using 'Primer Detectives' software (Clontech 
2.4. Western-blotting of Cyp2e-1 protein 
Microsomal proteins were obtained by centrifugation at
104,000 g for 60 min, from the 10,000 g supematant of 
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liver, kidney or hepatocyte homogenates, which were pre- 
pared by homogenization i  5 vol of 50 mM Tris-HCl, pH 
7.5, 0.15 M KC1 and 10 mM MgC12. 20-40 mg of the 
protein was resolved by SDS-PAGE, then transferred to a 
nitrocellulose membrane. The Cyp2e-I protein was reacted 
with polyclonal rabbit anti-rat CYP2EI antibody [40], 
followed by peroxidase-conjugated goat antibody against 
rabbit IgG(H+ L), then visualized with 3,Y-diamino- 
benzidine and hydrogen peroxide. 
3. Results 
3.1. Expression of  Cyp2e-] mRNA and protein after cas- 
tration 
Expressed amounts of Cyp2e-1 mRNA and protein in 
male and female livers we, re within the same range, and 
orchiectomy or ovariectorny did not affect the expression 
(Fig. 2). Cyp2e-1 expression was sexually dimorphic in the 
mouse kidney with higher levels in males than in females. 
More mRNA was expres,;ed in the female kidney after 
ovariectomy, whereas the contents of Cyp2e-I protein 
unchanged. Orchiectomy decreased the expression of 
mRNA and protein in the kidney. 
3.2. Expression of  Cyp2e-1 mRNA and protein in culture 
When the hepatocytes 'were transferred to primary cul- 
ture, the amount of the mRNA changed little within 24 h 
(Fig. 3A,C). The level decreased thereafter, declining to 
about half those before culture, by day 3. However, the 
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Fig. 3. Change of expression of Cyp2e-I in culture. Hepatocytes were 
cultured as monolayers orspheroids, and Cyp2e-I mRNA expression was 
measured daily. Microsomal proteins were prepared aily from spheroid 
cultures. The cells were incubated with 10-7 M dexamethasone for 24 h 
before harvest. Cyp2e-I expression was confirmed using 20 Ixg of 
microsomal protein as described inSection 2. A. Development of RT-PCR 
products on polyacrylamide electrophoresis. B. Western-blotting. C. 
Changes of RT-PCR products, Closed circle, monolayer culture; open 
squire, spheroid culture. D. Changes of Cyp2e-1 protein. Closed circle, 
control; open squire, 10 -7 M dexamethasone-treated. Amounts were 
measured with a densitometer and arbitrarily determined with a day 0 
sample as 100. Each point shows the mean +__ S.D. (n = 3). 
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Fig. 2. Expression of Cyp2e-1 in mouse liver and kidney. Male 
C57BL/6NCrj mice were orchiectomized and females ovariectomized at 
4 wk old. The animals were killed 4 weeks later and total RNAs were 
prepared from the livers and kidneys. Total RNA was reverse-transcribed, 
then amplified as described inSection 2. Microsomal proteins of liver (20 
Ixg) and kidney (40 Ixg) were ~malyzed byWestern-blotting. 1, Untreated 
male; 2, Orchiectomized male; 3, Untreated female; 4, Ovariectomized 
female. 
expression was very low by day 5 or later. The decreasing 
curve with monolayers was a little rapid compared with 
that with spheroids, the latter culture system being conve- 
nient for maintaining the in vivo level expression of 
Cypla-2,  Cyp2b-9 and Cyp2b-10 [34,41]. The level of 
Cyp2e-1 protein gradually decreased after transferring the 
cells to culture (Fig. 3B,D). Dexamethasone increased the 
amounts of Cyp2e-1 apoprotein. Interestingly the amounts 
in hepatocytes cultured for 24 h in the presence of dexa- 
methasone were higher than those before culture, In the 
following in vitro experiments the ceils were cultured as 
spheroids. 
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Fig. 4. Induction of Cyp2e-I mRNA by dexamethasone. Hepatocytes on 
days 1, 3 or 4, were incubated with the indicated concentrations of
dexamethasone (Dex) and total RNA was prepared 6, 12 or 24 h later. 
RT-PCR proceeded as described in the legend to Fig. 2. Expression of 
Cyp2e-I mRNA on either day 1 or 4 was measured after incubation for 
12 h with Dex. 
GAPDH 
Fig. 6. Effect of actinomycin D on the expression of Cyp2e-1 mRNA by 
dexamethasone. Hepatocytes on day 3 were exposed to the indicated 
concentrations of dexamethasone i  the presence or absence of actino- 
mycin D at 1 fxg/ml. Total RNA was prepared 6 or 11 h later and 
Cyp2e-I mRNA expression was analyzed by RT-PCR. 
13-Estradiol(-IogM) Testosterone(-IogM) 
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3.3. Expressions of Cyp2e-I mRNA and protein induced by 
dexamethasone 
Fig. 4 shows the enhanced expression of Cyp2e-I 
mRNA in the presence of dexamethasone in the medium. 
Even if the glucocorticoid hormone in the medium was 
depleted for 72 or 96 h, its addition increased the expres- 
sion. The expression was elevated at 10-8-10 _6 M dexa- 
methasone. The mRNA peaked 12 h after adding dexa- 
methasone. With 10 -6 M dexamethasone, the amounts 
increased 11.0 +__ 2.5 (n = 4)-fold for the control. How- 
ever, there was no increase on day 1. GADPH mRNA 
expression was not affected by dexamethasone, suggesting 
that an elevation in glucocorticoid concentration is not 
necessary for fundamental functions of hepatocytes. When 
added to the medium from the start of cultivation, Cyp2e- 1 
protein expression on day 3 was maximal at 10 -7 M 
dexamethasone (Fig. 5). Microsomes in hepatocytes incu- 
bated with the glucocorticoid hormone for 24 h before 
harvest contained higher levels of P-450 proteins than 
those in untreated cells until day 3 (Fig. 3B,D). The 
induction of Cyp2e- 1 mRNA by dexamethasone was inhib- 
ited by actinomycin D(Fig. 6). 
3.4. Effects of sex and growth hormones on Cyp2e-1 
mRNA expression 
We examined the effects of other endogenous hor- 
mones, which alter the expression of various constitutive 
0 10 "s 10 "7 10 4 Dexamethasone(M)  
Fig. 7. Effect of sex and growth hormones on the expression of Cyp2e-I 
mRNA. Hepatocytes on day 3 were incubated with 13-estradiol r testos- 
terone at the indicated concentrations or with 10 mU/ml recombinant 
human growth hormone and/or 10 -7 M dexamethasone, and total RNA 
was prepared 12 h later. RT-PCR proceeded as described in the legend to 
Fig. 2. a, Control; b, Growth hormone; c, Dexamethasone; d, Growth 
hormone +dexamethasone. 
P-450 species [35,42,43], upon Cyp2e-I mRNA expres- 
sion. Testosterone and 13-estradiol increased the levels of 
the mRNA up to 2.7-fold at 10-7 -10  -9  M (Fig. 7). 
Although the increase was not so much as observed after 
dexamethasone, it should be examined whether or not sex 
hormones might play any role for the expression in vivo, 
especially in the liver. Furthermore, growth hormone did 
not suppress the expression of either constitutive or dexa- 
methasone-treated h patocytes. Other chemicals that influ- 
ence CYP2E1 expression i  vivo, such as ethanol, acetone, 
pyrazole and diethylnitrosamine, did not induce Cyp2e-1 
mRNA. However, 10 mM acetone, at which concentration 
there was no apparent alteration of GADPH expression, 
reduced the level of mRNA (Fig. 8). 
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Fig. 5. Induction of Cyp2e-1 protein by dexamethasone. Microsomal 
proteins were prepared from hepatocytes icubated with 10-8-10 -6 M 
dexamethasone for 72 h from the start of the culture. Protein (20 ixg) was 
Western-blotted. 
Fig. 8. Effects of organic chemicals on Cyp2e-l mRNA expression. 
Hepatocytes on day 3 were treated with the indicated agents and total 
RNA was prepared 12 h later. RT-PCR proceeded as described in the 
legend to Fig. 2. C, Control; DEN, Diethylnitrosamine; P, 1 mM Pheno- 
barbital; M, 10 I, LM 3-Methylcholanthrene; D, 10 -7 M dexamethasone. 
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4. Discussion 
CYP2E1 is expressed in various organs, the liver being 
at the highest level. Several investigators, however, have 
reported that primary culture of hepatocytes cannot main- 
tain CYP2E1 expression [1,7,32,33]. Less than 10% of 
CYP2E1 mRNA isolated from livers of starved or 
acetone-treated rats remained at 24 h and it became unde- 
tectable afterwards [7]. In contrast, the presence of iigand 
in the medium prevented the.. loss of the P-450 protein and 
about 70% of the original amounts were present even after 
three days in culture. In this; studies, we found that mouse 
hepatocytes in either monolayer or spheroid culture main- 
tained the mRNA expression for a longer period than that 
reported [7,32,33]. Furthermore, we examined Cyp2e-1 
mRNA and protein induction in these cultures. 
CYP2E1 expression is altered at the protein level by 
small organic chemicals, such as acetone, ethanol, chloro- 
form and pyrazole, in mouse, rat and rabbit liver [1-17]. 
Furthermore, patho-physiological states altered by starva- 
tion or diabetes elevate the expression at the mRNA level 
[8,12,19,44-46]. In the developmental regulation, tran- 
scriptional activation is responsible for the rapid increase 
of this enzyme after parturition [47,48]. This evidence 
suggests that endogenous hormones influence transcription 
of the CYP2E1 gene. Hypophysectomy causes elevated 
expressions of both CYP2E1 mRNA and protein in the rat 
liver, indicating that pituitary hormones play important 
roles in the regulation of the CYP2EI expression either by 
repressing gene transcription or by enhancing mRNA 
degradation [28,49]. However, which hormone(s) excreted 
from pituitary is involved in the regulation remains un- 
known. Growth hormone suppresses the expression of 
several P-450 species [1..50-54]. However, there is a 
species difference in the regulation between rats and mice. 
No statistically significant alterations in either the activity 
of liver microsomal N-nitrosodimethylamine demethylase, 
a marker enzyme for Cyp2e-1, or in Cyp2e-1 protein 
content have been reported in hypophysectomized or 
growth hormone-deficient mutant mice [28]. Ketone bodies 
have been proposed as mediators in the induction of 
CYP2E1, based on the fact that CYP2E1 activity is in- 
duced by acetone or isopropanol as well as in ketonic 
conditions such as fasting and diabetes [12]. However, 
hypophysectomy did not elevate the level of ketone bodies 
in the blood [28]. In this sUldy, glucocorticoid hormone has 
the potential to induce Cyp2e-1 mRNA in hepatocyte 
culture. The secretion of glucocorticoid hormone from the 
adrenals is controlled by pituitary ACTH by means of a 
negative feedback mecihanism. Thus, understanding 
whether or not elevated adrenal hormone levels in the 
blood due to non-regulal:ed production in hypophysec- 
tomized animals influence Cyp2e-1 mRNA synthesis 
should be informative. 
Existence of dexamethasone from the start of culture 
increased the Cyp2e-1 apoprotein (Fig. 3B, D), suggesting 
that glucocorticoids are required for its maintenance in
differentiated hepatocytes. However, induction of Cyp2e-1 
mRNA by dexamethasone was not observed in the liver or 
during early hepatocyte culture, when basic expression was 
equivalent to the in vivo level, but was prominent at day 3 
or later. Although transcription or stabilization of the 
mRNA explains the increase of Cyp2e-1 expression in 
diabetic or fasting animals [19], there have been a few 
report which showed an increase in mRNA amounts in 
vitro. However, our observations that actinomycin D re- 
duced the expression of the mRNA indicate that transcrip- 
tion of the Cyp2e-1 gene might be activated by dexametha- 
sone. The concentrations of dexamethasone required for 
the induction were very low (Fig. 4). Therefore, the con- 
centration of glucocorticoid hormone in mouse hepatocytes 
during early culture might be sufficient o maintain the 
expression and dexamethasone failed to further elevate it. 
Treatment with dexamethasone three times daily at 10 or 
100 mg/kg body wt. did not change the levels of Cyp2e-I 
mRNA or protein in male and female livers and kidney 
(unpublished ata). However, as the hormone contents 
decreased over the culture period, dexamethasone i duced 
Cyp2e-1 mRNA. The other possibility is that the suppres- 
sion of dexamethasone-inducible expression would be re- 
duced by culture. These possibilities hould be investi- 
gated, since both suggest that glucocorticoid hormone 
plays a role in the fundamental transcription of the Cyp2e- 1 
gene. 
Studies on the regulation mechanism of cytochrome 
P-450s, such as CYP2A1, CYP2A2, CYP2Cll and 
CYP2C12, which are involved in the biosynthesis of sex- 
related steroids, have revealed that their expression levels 
change after exposure to androgens or estrogens [42,43]. 
However, it is not well understood whether other P-450s, 
the expression of which differs between males and fe- 
males, are regulated by sex hormones. We reported that 
male and female hormones induced Cyp2b-9 and Cyp2b-10 
in mouse hepatocyte culture [35]. Several investigators 
have demonstrated that testosterone r gulates the renal (but 
not hepatic) activity of Cyp2e-1 [4,20-24,26,27,48]. We 
also obtained the same results in castrated animals, sug- 
gesting that androgens have important roles in Cyp2e-1 
mRNA expression in the kidney. However, either andro- 
gen or estrogen slightly changed the expression of this 
P-450 species in cultured mouse hepatocytes. The level of 
androgen receptors did not decrease during hepatocyte 
culture, since various male hormones and cyproterone, 
which antagonizes androgens by competitively binding to 
their receptors, can induce Cyp2b-9 and Cyp2 -10 mRNA 
in the same culture system [35]. Furthermore, dexametha- 
sone does not bind to the androgen receptor and testos- 
terone does not bind to the glucocorticoid receptor [55]. 
This evidence suggests that there are several mechanisms 
for Cyp2e-1 mRNA expression and that the major regula- 
tory pathways differ between the liver and kidney. 
De novo synthesis of CYP2E1 mRNA has been identi- 
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fled by Kraner et al. [56] in rabbit hepatocytes in primary 
culture. They found an increase in the mRNA amounts (at 
most 60% higher than the untreated control value) by 
acetone. However, although acetone induced Cyp2e-1 pro- 
tein, it reduced the mRNA level in the liver or kidney [16]. 
CYP2E1 mRNA levels in animals, in which CYP2E1 
enzyme activities were elevated, decrease in pyridine- 
treated rats [1 I] and ethanol-treated rabbits [17]. In this 
study, acetone at a high concentration reduced Cyp2e-1 
expression. Furthermore, Kraner et al. [56] did not demon- 
strate any description on alteration of CYP2E1 mRNA 
expression after establishing primary cultures. Thus, mouse 
hepatocyte culture might reflect he in vivo response more 
precisely than the rabbit system. 
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